Related Experiment Video
Updated: Jul 1, 2025
09:43
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
2.9K
Differences in management approaches for lupus nephritis within the UK
Sara T Ibrahim1,2, Christopher J Edwards3, Michael R Ehrenstein4
1Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK.
Rheumatology Advances in Practice
|March 12, 2024
Summary
UK physicians show varied approaches to treating lupus nephritis (LN). Treatment preferences for class IV and V LN differ between rheumatologists and nephrologists, highlighting a need for standardized care protocols.
Area of Science:
- Nephrology
- Rheumatology
- Immunology
Background:
- Lupus nephritis (LN) outcomes are often suboptimal.
- Treatment guidelines for LN offer varied options.
- Clinical practice strategies for LN management differ across clinicians and regions.
Purpose of the Study:
- To assess variations in the usual practice of UK physicians treating lupus nephritis (LN).
- To identify treatment preferences for class IV and class V LN among UK rheumatologists and nephrologists.
Main Methods:
- An online survey of simulated LN cases was conducted.
- UK rheumatologists and nephrologists were surveyed.
- Treatment preferences for class IV and V LN were identified.
Main Results:
- Significant variations exist in the use of protocols, specialist clinic services, and biopsy practices.
- Mycophenolate mofetil (MMF) was the preferred initial treatment for class IV and V LN.
- Differences in primary and secondary treatment choices were reported between nephrologists and rheumatologists.
Conclusions:
- There is considerable variation in the management of lupus nephritis (LN) among UK nephrologists and rheumatologists.
- Variations include the use of protocols, specialist clinic provision, biopsy practices, and treatment choices.
- Standardization of LN treatment protocols may improve patient outcomes.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
01:28Pulmonary Tuberculosis V
179
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
179
01:11Renal Failure: Dose Adjustments
88
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
88
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
429
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
429
01:28Pneumonia IV: Management
324
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
324
01:29Chronic Pancreatitis II: Collaborative Care
88
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
88